Melanoma Clinical Trials in Arizona

Showing 61-80 of 129 trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+7 more

OncoResponse, Inc.172 participantsStarted Sep 2021

Scottsdale, Arizona, United States • Austin, Texas, United States • San Antonio, Texas, United States

TERMINATEDPHASE131 miles

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699

This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHodgkin Disease+17 more

Seagen Inc.159 participantsStarted Feb 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +16 more locations

PreviousPage 4 of 7Next

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Safety Study of SEA-CD40 in Cancer Patients

Melanoma Trials in Other Cities

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Safety Study of MGA271 in Refractory Cancer

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Other Conditions in Arizona